Beyond tumor necrosis factor inhibition: The expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae

S. A. Novosad, Kevin Winthrop

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher risk for infectious morbidity and mortality, partially due to the therapies used to treat these conditions. Both prednisone and targeted biologic therapies such as tumor necrosis factor antagonists have been implicated to various degrees, although in some cases firm data are lacking with regard to certain types of infections. To date, there is a paucity of information regarding the infectious risks associated with the newer biologic agents. As new biologic agents become available for use, their potential infectious risks will challenge infectious disease clinicians who must work to prevent, diagnose, and treat infections in this setting. This article reviews our current understanding of infectious risk in the setting of targeted therapies and provides an update of the immune system targets and potential infectious sequelae of both current and emerging biologic therapies.

Original languageEnglish (US)
Pages (from-to)1587-1598
Number of pages12
JournalClinical Infectious Diseases
Volume58
Issue number11
DOIs
StatePublished - Jun 1 2014

Fingerprint

Biological Therapy
Tumor Necrosis Factor-alpha
Biological Factors
Prednisone
Infection
Communicable Diseases
Immune System
Rheumatoid Arthritis
Morbidity
Mortality
Therapeutics

Keywords

  • Anti-TNF agents
  • Autoimmune disease
  • Biologic therapies
  • Infection
  • Opportunistic infections

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Medicine(all)

Cite this

@article{cb39a62c8d774f8fba68028e1869627d,
title = "Beyond tumor necrosis factor inhibition: The expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae",
abstract = "Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher risk for infectious morbidity and mortality, partially due to the therapies used to treat these conditions. Both prednisone and targeted biologic therapies such as tumor necrosis factor antagonists have been implicated to various degrees, although in some cases firm data are lacking with regard to certain types of infections. To date, there is a paucity of information regarding the infectious risks associated with the newer biologic agents. As new biologic agents become available for use, their potential infectious risks will challenge infectious disease clinicians who must work to prevent, diagnose, and treat infections in this setting. This article reviews our current understanding of infectious risk in the setting of targeted therapies and provides an update of the immune system targets and potential infectious sequelae of both current and emerging biologic therapies.",
keywords = "Anti-TNF agents, Autoimmune disease, Biologic therapies, Infection, Opportunistic infections",
author = "Novosad, {S. A.} and Kevin Winthrop",
year = "2014",
month = "6",
day = "1",
doi = "10.1093/cid/ciu104",
language = "English (US)",
volume = "58",
pages = "1587--1598",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Beyond tumor necrosis factor inhibition

T2 - The expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae

AU - Novosad, S. A.

AU - Winthrop, Kevin

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher risk for infectious morbidity and mortality, partially due to the therapies used to treat these conditions. Both prednisone and targeted biologic therapies such as tumor necrosis factor antagonists have been implicated to various degrees, although in some cases firm data are lacking with regard to certain types of infections. To date, there is a paucity of information regarding the infectious risks associated with the newer biologic agents. As new biologic agents become available for use, their potential infectious risks will challenge infectious disease clinicians who must work to prevent, diagnose, and treat infections in this setting. This article reviews our current understanding of infectious risk in the setting of targeted therapies and provides an update of the immune system targets and potential infectious sequelae of both current and emerging biologic therapies.

AB - Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher risk for infectious morbidity and mortality, partially due to the therapies used to treat these conditions. Both prednisone and targeted biologic therapies such as tumor necrosis factor antagonists have been implicated to various degrees, although in some cases firm data are lacking with regard to certain types of infections. To date, there is a paucity of information regarding the infectious risks associated with the newer biologic agents. As new biologic agents become available for use, their potential infectious risks will challenge infectious disease clinicians who must work to prevent, diagnose, and treat infections in this setting. This article reviews our current understanding of infectious risk in the setting of targeted therapies and provides an update of the immune system targets and potential infectious sequelae of both current and emerging biologic therapies.

KW - Anti-TNF agents

KW - Autoimmune disease

KW - Biologic therapies

KW - Infection

KW - Opportunistic infections

UR - http://www.scopus.com/inward/record.url?scp=84900402102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900402102&partnerID=8YFLogxK

U2 - 10.1093/cid/ciu104

DO - 10.1093/cid/ciu104

M3 - Article

C2 - 24585557

AN - SCOPUS:84900402102

VL - 58

SP - 1587

EP - 1598

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -